Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

TAIPEI, TAIWAN (UroToday.com) - Introduction and Objectives: To analyze oncological outcomes after radical prostatectomy for high-risk prostate cancers.


Methods: From November 1996 to January 2014, all D’Amico high-risk prostate cancers with radical prostatectomy performed were included. Pathological and oncological outcomes were analyzed.

wceResults: 92 patients with 24 open, 7 laparosocopic, and 61 robotic prostatectomies were included. Pre-operative mean PSA was 25.4 + / - 23 ng/ml, and 48.9% had palpable prostate nodule. 57.6% patients had pre-operative Gleason score 8–10. Pathological staging showed 25.0% T2c, 31.5% T3a and 25.0% T3b. Pathological N1 was seen in 8.7% patients. There were 35.2% Gleason 7 and 34.3% Gleason 8–10. Positive surgical margin rate was 34.8%. There was a trend towards lower positive surgical margins in robotic group (29.5%) compared with laparoscopic (42.9%) and open (45.8%) groups. Excluding 13 patients with early post-operative androgen deprivation therapy (ADT), 71.8% had undetectable PSA nadir, and there was no difference comparing different surgical approaches. At a median follow-up of 4.5 (range 0.1–17.5) years, 18.2% had biochemical recurrence, 11.7% had adjuvant radiotherapy, 10.4% had salvage radio-therapy, 14.4% had early ADT, 22.2% had late ADT, 6.7% had metastasis, 3.3% reached castration resistant status, and 3.3% died of prostate cancer. On the whole, 48.9% patients required adjuvant therapy. For patients with N1 disease with early ADT given, 12.5% had castration resistance but none of them died at a median follow-up of 10 years.

Conclusions: Radical prostatectomy with adjuvant therapy provided good cancer control and long-term survival in high-risk prostate cancers.

Source of Funding: None

 
Listen to an interview with Peter Ka-Fung Chiu, one of the authors of this study.

Presented by Peter Ka-Fung Chiu, Kim W.M. Lee, 
Simon S.M. Hou, Chi-Fai Ng at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan

Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong

 

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Calendar
Upcoming urology industry events
August 28-31, 2018 / ICS 2018
International Continence Society 2018
September 1-3, 2018 / European Society for Medical Oncology Academy 2018
European Society for Medical Oncology Academy 2018
September 5-8, 2018 / Fairmont Hotel, Chicago, IL
92nd Annual Meeting of the North Central Section of the AUA
Journals
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 1

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor